[The efficacy and safety of nafarelin in treating genital endometriosis].

Akusherstvo i ginekologiia · 1996 · vol. 35(1-2) , pp. 63–6 · PMID:8967550 · W2410636626
article OA: closed CC0
View on OpenAlex View on PubMed

Abstract

A prospective study was carried out a State Institute Hospital "Maĭchin dom" aiming to estimate the efficacy of GnRH-agonist Nafarelin in treating patients with endometriosis. Nafarelin was used by 40 women with endometriosis. The drug was applied as a nasal spray according to a therapeutic scheme and regarding definite criteria. Every patient was followed while using the drug and the following sings were registered: occurrence of amenorrhea, clinical sings, side effects, the period of control lasting for a year after the end of the treatment. In 27 women a quick and long-lasting amenorrhoea was induced with standard doses of the drug, while other 13 needed higher dosage to achieve the same effect. Relief of complaints was registered on 35 women. Improved palpatory status was found in 23 patients. In 4 women the disappearance of endometriomas was confirmed by laparoscopy. The existing side-effects are dos to the appearing hypoestrogenemia. After treatment with Nafarelin, during the period of observation, 5 women got pregnant.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Hormones Nafarelin Administration, Intranasal Adolescent Adult Amenorrhea Amenorrhea Drug Evaluation Endometriosis Female Hormones Hormones Humans Nafarelin Nafarelin Prospective Studies Time Factors

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:08.331550+00:00
License: CC0 · commercial use OK